FluMist is a nasal spray manufactured by AstraZeneca that has been used to protect against influenza in the United States ...

The vaccine FluMist, manufactured by MedImmune, which was acquired by AstraZeneca in 2007, was first approved by the FDA in 2003 for individuals between five and 49 years of age. Its approval has ...

Recent health developments include the EU backing Novo Nordisk's Wegovy for obesity-related heart conditions, FDA approvals ...

The Food and Drug Administration announced Friday it had broadened the approval of the FluMist nasal spray to become the first “self-administered” influenza vaccine — though a delay in the change ...

The AstraZeneca PLC ADR AZN slumped 0.66% to $78.38 Friday, on what proved to be an all-around mixed trading session for the ...

Instead of four equal quarterly distributions, AstraZeneca insists on two payments per year, with a greater portion announced ...

The AstraZeneca PLC ADR AZN inched 0.06% higher to $78.58 Wednesday, on what proved to be an all-around dismal trading ...

JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the ...

Approximately half of EGPA patients also have adult-onset severe eosinophilic asthma, or SEA, for which Fasenra is only the second biologic approved treatment. Fasenra is now approved as an add-on ...

AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...

Amylin is a hormone co-secreted with insulin in the pancreas that has anorexigenic effects, since it promotes satiety and reduces food intake. Amylin analogs and dual agonists of the amylin and ...

Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ETCompany ParticipantsPascal Soriot - Chief ...